Reduced airway levels of fatty-acid binding protein 4 in COPD: relationship with airway infection and disease severity

Background: For still unclear reasons, chronic airway infection often occurs in patients with Chronic Obstructive Pulmonary Disease (COPD), particularly in those with more severe airflow limitation. Fatty-acid binding protein 4 (FABP4) is an adipokine involved in the innate immune response against i...

Descripción completa

Detalles Bibliográficos
Autores: Perea, Lídia, Rodrigo-Troyano, Ana, Cantó, Elisabet, Domínguez-Álvarez, Marisol, Giner Donaire, Jordi, Sanchez-Reus, Ferran, Villar-García, Judit, Quero, Sara, García-Núñez, Marian, Marín, Alicia, Monsó, Eduard, Faner, Rosa, Agustí García-Navarro, Àlvar, Vidal, Silvia, Sibila Vidal, Oriol
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/174075
Acceso en línea:https://hdl.handle.net/2445/174075
Access Level:acceso abierto
Palabra clave:Malalties pulmonars obstructives cròniques
Macròfags
Chronic obstructive pulmonary diseases
Macrophages
id ES_9d7d5f4b392d3e7be49e13b5bb5613db
oai_identifier_str oai:diposit.ub.edu:2445/174075
network_acronym_str ES
network_name_str España
repository_id_str
spelling Reduced airway levels of fatty-acid binding protein 4 in COPD: relationship with airway infection and disease severityPerea, LídiaRodrigo-Troyano, AnaCantó, ElisabetDomínguez-Álvarez, MarisolGiner Donaire, JordiSanchez-Reus, FerranVillar-García, JuditQuero, SaraGarcía-Núñez, MarianMarín, AliciaMonsó, EduardFaner, RosaAgustí García-Navarro, ÀlvarVidal, SilviaSibila Vidal, OriolMalalties pulmonars obstructives cròniquesMacròfagsChronic obstructive pulmonary diseasesMacrophagesBackground: For still unclear reasons, chronic airway infection often occurs in patients with Chronic Obstructive Pulmonary Disease (COPD), particularly in those with more severe airflow limitation. Fatty-acid binding protein 4 (FABP4) is an adipokine involved in the innate immune response against infection produced by alveolar macrophages (Mɸ). We hypothesized that airway levels of FABP4 may be altered in COPD patients with chronic airway infection. Methods: In this prospective and controlled study we: (1) compared airway FABP4 levels (ELISA) in induced sputum, bronchoalveolar lavage fluid (BALF) and plasma samples in 52 clinically stable COPD patients (65.2 ± 7.9 years, FEV1 59 ± 16% predicted) and 29 healthy volunteers (55.0 ± 12.3 years, FEV1 97 ± 16% predicted); (2) explored their relationship with the presence of bacterial airway infection, defined by the presence of potentially pathogenic bacteria (PPB) at ≥103 colony-forming units/ml in BALF; (3) investigated their relationship with the quantity and proportion of Mɸ in BALF (flow cytometry); and, (4) studied their relationship with the severity of airflow limitation (FEV1), GOLD grade and level of symptoms (CAT questionnaire). Results: We found that: (1) airway levels of FABP4 (but not plasma ones) were reduced in COPD patients vs. controls [219.2 (96.0-319.6) vs. 273.4 (203.1-426.7) (pg/ml)/protein, p = 0.03 in BALF]; (2) COPD patients with airway infection had lower sputum FABP4 levels [0.73 (0.35-15.3) vs. 15.6 (2.0-29.4) ng/ml, p = 0.02]; (3) in COPD patients, the number and proportion of Mɸ were positively related with FABP4 levels in BALF; (4) BALF and sputum FABP4 levels were positively related with FEV1, negatively with the CAT score, and lowest in GOLD grade D patients. Conclusions: Airway FABP4 levels are reduced in COPD patients, especially in those with airway infection and more severe disease. The relationship observed between Mɸ and airway FABP4 levels supports a role for FABP4 in the pathogenesis of airway infection and disease severity in COPD.BioMed Central2020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/174075Articles publicats en revistes (Medicina)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.1186/s12931-020-1278-5Respiratory Research, 2020, vol. 21, num. 1https://doi.org/10.1186/s12931-020-1278-5cc-by (c) Perea, Lídia et al., 2020http://creativecommons.org/licenses/by/3.0/esinfo:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1740752026-05-27T06:46:51Z
dc.title.none.fl_str_mv Reduced airway levels of fatty-acid binding protein 4 in COPD: relationship with airway infection and disease severity
title Reduced airway levels of fatty-acid binding protein 4 in COPD: relationship with airway infection and disease severity
spellingShingle Reduced airway levels of fatty-acid binding protein 4 in COPD: relationship with airway infection and disease severity
Perea, Lídia
Malalties pulmonars obstructives cròniques
Macròfags
Chronic obstructive pulmonary diseases
Macrophages
title_short Reduced airway levels of fatty-acid binding protein 4 in COPD: relationship with airway infection and disease severity
title_full Reduced airway levels of fatty-acid binding protein 4 in COPD: relationship with airway infection and disease severity
title_fullStr Reduced airway levels of fatty-acid binding protein 4 in COPD: relationship with airway infection and disease severity
title_full_unstemmed Reduced airway levels of fatty-acid binding protein 4 in COPD: relationship with airway infection and disease severity
title_sort Reduced airway levels of fatty-acid binding protein 4 in COPD: relationship with airway infection and disease severity
dc.creator.none.fl_str_mv Perea, Lídia
Rodrigo-Troyano, Ana
Cantó, Elisabet
Domínguez-Álvarez, Marisol
Giner Donaire, Jordi
Sanchez-Reus, Ferran
Villar-García, Judit
Quero, Sara
García-Núñez, Marian
Marín, Alicia
Monsó, Eduard
Faner, Rosa
Agustí García-Navarro, Àlvar
Vidal, Silvia
Sibila Vidal, Oriol
author Perea, Lídia
author_facet Perea, Lídia
Rodrigo-Troyano, Ana
Cantó, Elisabet
Domínguez-Álvarez, Marisol
Giner Donaire, Jordi
Sanchez-Reus, Ferran
Villar-García, Judit
Quero, Sara
García-Núñez, Marian
Marín, Alicia
Monsó, Eduard
Faner, Rosa
Agustí García-Navarro, Àlvar
Vidal, Silvia
Sibila Vidal, Oriol
author_role author
author2 Rodrigo-Troyano, Ana
Cantó, Elisabet
Domínguez-Álvarez, Marisol
Giner Donaire, Jordi
Sanchez-Reus, Ferran
Villar-García, Judit
Quero, Sara
García-Núñez, Marian
Marín, Alicia
Monsó, Eduard
Faner, Rosa
Agustí García-Navarro, Àlvar
Vidal, Silvia
Sibila Vidal, Oriol
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Malalties pulmonars obstructives cròniques
Macròfags
Chronic obstructive pulmonary diseases
Macrophages
topic Malalties pulmonars obstructives cròniques
Macròfags
Chronic obstructive pulmonary diseases
Macrophages
description Background: For still unclear reasons, chronic airway infection often occurs in patients with Chronic Obstructive Pulmonary Disease (COPD), particularly in those with more severe airflow limitation. Fatty-acid binding protein 4 (FABP4) is an adipokine involved in the innate immune response against infection produced by alveolar macrophages (Mɸ). We hypothesized that airway levels of FABP4 may be altered in COPD patients with chronic airway infection. Methods: In this prospective and controlled study we: (1) compared airway FABP4 levels (ELISA) in induced sputum, bronchoalveolar lavage fluid (BALF) and plasma samples in 52 clinically stable COPD patients (65.2 ± 7.9 years, FEV1 59 ± 16% predicted) and 29 healthy volunteers (55.0 ± 12.3 years, FEV1 97 ± 16% predicted); (2) explored their relationship with the presence of bacterial airway infection, defined by the presence of potentially pathogenic bacteria (PPB) at ≥103 colony-forming units/ml in BALF; (3) investigated their relationship with the quantity and proportion of Mɸ in BALF (flow cytometry); and, (4) studied their relationship with the severity of airflow limitation (FEV1), GOLD grade and level of symptoms (CAT questionnaire). Results: We found that: (1) airway levels of FABP4 (but not plasma ones) were reduced in COPD patients vs. controls [219.2 (96.0-319.6) vs. 273.4 (203.1-426.7) (pg/ml)/protein, p = 0.03 in BALF]; (2) COPD patients with airway infection had lower sputum FABP4 levels [0.73 (0.35-15.3) vs. 15.6 (2.0-29.4) ng/ml, p = 0.02]; (3) in COPD patients, the number and proportion of Mɸ were positively related with FABP4 levels in BALF; (4) BALF and sputum FABP4 levels were positively related with FEV1, negatively with the CAT score, and lowest in GOLD grade D patients. Conclusions: Airway FABP4 levels are reduced in COPD patients, especially in those with airway infection and more severe disease. The relationship observed between Mɸ and airway FABP4 levels supports a role for FABP4 in the pathogenesis of airway infection and disease severity in COPD.
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/174075
url https://hdl.handle.net/2445/174075
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1186/s12931-020-1278-5
Respiratory Research, 2020, vol. 21, num. 1
https://doi.org/10.1186/s12931-020-1278-5
dc.rights.none.fl_str_mv cc-by (c) Perea, Lídia et al., 2020
http://creativecommons.org/licenses/by/3.0/es
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Perea, Lídia et al., 2020
http://creativecommons.org/licenses/by/3.0/es
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv BioMed Central
publisher.none.fl_str_mv BioMed Central
dc.source.none.fl_str_mv Articles publicats en revistes (Medicina)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869414747140521984
score 15.300719

Similares en LA Referencia